risks of taking compounded semaglutide I Microdosed at 0.1 mg Weekly for 6 Months — Here's What Actually Happened Compounded Semaglutide: What to Know

This blog identifies three categories of topics that are relevant to prescribing compounded GLP-1s

Resources: www.cdc.gov/obesity/data/adult.html www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html www.cdc.gov/obesity/about-obesity/why-it-matters.html www.usnews.com/news/best-states/articles/2021-09-15/the-pandemic-has-worsened-americas-obesity-epidemic-report-finds www.npr.org/sections/health-shots/2021/09/29/1041515129/obesity-rates-rise-during-pandemic-fueled-by-stress-job-loss-sedentary-lifestyle Time for Medical Coder and Auditor Training - July 1, 2025 Unlisted But Not Unpaid - December 2, 2024 Case Study Targets E/M Services in the ED - June 3, 2024 9 Responses to Coding Obesity and Medical Nutrition Therapy Excellent information

, : 22.5% (SURMOUNT-1 , 72) : 14.9% (STEP-1 , 68) ,

Short-term weight loss followed by high rates of dropout, weight regain, and prolonged medication use

GLP-1 medications are prescription treatments and should be used only under the guidance of a licensed healthcare professional